Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

96.30
Delayed Data
As of 4:05pm ET
 -1.05 / -1.08%
Today’s Change
59.27
Today|||52-Week Range
98.87
+53.78%
Year-to-Date
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
4:08pm / Zacks.com - Paid Partner Content
AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
Dec 05 / Zacks.com - Paid Partner Content
Roche/AbbVie Report Positive Phase III Results on Venclexta
Dec 13 / Zacks.com - Paid Partner Content
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
Dec 04 / Zacks.com - Paid Partner Content
Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug
Dec 12 / Zacks.com - Paid Partner Content
3 Drug/Biotech Stocks in Focus on World AIDS Day
Dec 01 / Zacks.com - Paid Partner Content
Novartis Announces Positive Data on Sickle Cell Disease Drug
Dec 12 / Zacks.com - Paid Partner Content
AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
Nov 30 / Zacks.com - Paid Partner Content
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
Dec 06 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
Nov 30 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
Dec 06 / Zacks.com - Paid Partner Content